Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 19

1.

Strategies to generate high-titer, high-potency recombinant AAV3 serotype vectors.

Ling C, Yin Z, Li J, Zhang D, Aslanidi G, Srivastava A.

Mol Ther Methods Clin Dev. 2016 May 4;3:16029. doi: 10.1038/mtm.2016.29. eCollection 2016.

2.

Adeno-Associated Virus: The Naturally Occurring Virus Versus the Recombinant Vector.

Srivastava A.

Hum Gene Ther. 2016 Jan;27(1):1-6. doi: 10.1089/hum.2015.29017.asr. No abstract available.

3.

Photoreceptor-targeted gene delivery using intravitreally administered AAV vectors in dogs.

Boyd RF, Sledge DG, Boye SL, Boye SE, Hauswirth WW, Komáromy AM, Petersen-Jones SM, Bartoe JT.

Gene Ther. 2016 Feb;23(2):223-30. doi: 10.1038/gt.2015.96. Epub 2015 Oct 15. Erratum in: Gene Ther. 2016 Apr;23(4):400.

4.

Progresses towards safe and efficient gene therapy vectors.

Chira S, Jackson CS, Oprea I, Ozturk F, Pepper MS, Diaconu I, Braicu C, Raduly LZ, Calin GA, Berindan-Neagoe I.

Oncotarget. 2015 Oct 13;6(31):30675-703. doi: 10.18632/oncotarget.5169. Review.

5.

Proteomics analysis of co-purifying cellular proteins associated with rAAV vectors.

Dong B, Duan X, Chow HY, Chen L, Lu H, Wu W, Hauck B, Wright F, Kapranov P, Xiao W.

PLoS One. 2014 Feb 3;9(2):e86453. doi: 10.1371/journal.pone.0086453. eCollection 2014.

6.

Adeno-associated virus capsid proteins may play a role in transcription and second-strand synthesis of recombinant genomes.

Salganik M, Aydemir F, Nam HJ, McKenna R, Agbandje-McKenna M, Muzyczka N.

J Virol. 2014 Jan;88(2):1071-9. doi: 10.1128/JVI.02093-13. Epub 2013 Nov 6.

7.

Bioengineering of AAV2 capsid at specific serine, threonine, or lysine residues improves its transduction efficiency in vitro and in vivo.

Gabriel N, Hareendran S, Sen D, Gadkari RA, Sudha G, Selot R, Hussain M, Dhaksnamoorthy R, Samuel R, Srinivasan N, Srivastava A, Jayandharan GR.

Hum Gene Ther Methods. 2013 Apr;24(2):80-93. doi: 10.1089/hgtb.2012.194. Epub 2013 Mar 15.

8.

Engineered AAV vector minimizes in vivo targeting of transduced hepatocytes by capsid-specific CD8+ T cells.

Martino AT, Basner-Tschakarjan E, Markusic DM, Finn JD, Hinderer C, Zhou S, Ostrov DA, Srivastava A, Ertl HC, Terhorst C, High KA, Mingozzi F, Herzog RW.

Blood. 2013 Mar 21;121(12):2224-33. doi: 10.1182/blood-2012-10-460733. Epub 2013 Jan 16.

9.

Development of Novel Recombinant AAV Vectors and Strategies for the Potential Gene Therapy of Hemophilia.

Zhong L, Jayandharan GR, Aslanidi GV, Zolotukhin S, Herzog RW, Srivastava A.

J Genet Syndr Gene Ther. 2012 Jan 10;S1. pii: 008.

10.

Adeno-associated virus-coated allografts: a novel approach for cranioplasty.

Ben Arav A, Pelled G, Zilberman Y, Kimelman-Bleich N, Gazit Z, Schwarz EM, Gazit D.

J Tissue Eng Regen Med. 2012 Nov;6(10):e43-50. doi: 10.1002/term.1594. Epub 2012 Sep 3.

11.

Intracellular transport of recombinant adeno-associated virus vectors.

Nonnenmacher M, Weber T.

Gene Ther. 2012 Jun;19(6):649-58. doi: 10.1038/gt.2012.6. Epub 2012 Feb 23. Review.

12.

Inflammation and immune response of intra-articular serotype 2 adeno-associated virus or adenovirus vectors in a large animal model.

Ishihara A, Bartlett JS, Bertone AL.

Arthritis. 2012;2012:735472. doi: 10.1155/2012/735472. Epub 2012 Jan 11.

13.

Self-complementary adeno-associated viral vectors for gene therapy of hemophilia B: progress and challenges.

Raj D, Davidoff AM, Nathwani AC.

Expert Rev Hematol. 2011 Oct;4(5):539-49. doi: 10.1586/ehm.11.48. Review.

14.

A simple method to increase the transduction efficiency of single-stranded adeno-associated virus vectors in vitro and in vivo.

Ma W, Li B, Ling C, Jayandharan GR, Srivastava A, Byrne BJ.

Hum Gene Ther. 2011 May;22(5):633-40. doi: 10.1089/hum.2010.243.

15.

Adeno-associated virus: a key to the human genome?

Henckaerts E, Linden RM.

Future Virol. 2010 Sep 1;5(5):555-574.

16.

High-efficiency transduction and correction of murine hemophilia B using AAV2 vectors devoid of multiple surface-exposed tyrosines.

Markusic DM, Herzog RW, Aslanidi GV, Hoffman BE, Li B, Li M, Jayandharan GR, Ling C, Zolotukhin I, Ma W, Zolotukhin S, Srivastava A, Zhong L.

Mol Ther. 2010 Dec;18(12):2048-56. doi: 10.1038/mt.2010.172. Epub 2010 Aug 24.

17.

Enhanced long-term transduction and multilineage engraftment of human hematopoietic stem cells transduced with tyrosine-modified recombinant adeno-associated virus serotype 2.

Kauss MA, Smith LJ, Zhong L, Srivastava A, Wong KK Jr, Chatterjee S.

Hum Gene Ther. 2010 Sep;21(9):1129-36. doi: 10.1089/hum.2010.016.

18.

Evading the immune response upon in vivo gene therapy with viral vectors.

Sack BK, Herzog RW.

Curr Opin Mol Ther. 2009 Oct;11(5):493-503. Review.

19.

Optimized adeno-associated virus (AAV)-protein phosphatase-5 helper viruses for efficient liver transduction by single-stranded AAV vectors: therapeutic expression of factor IX at reduced vector doses.

Jayandharan GR, Zhong L, Sack BK, Rivers AE, Li M, Li B, Herzog RW, Srivastava A.

Hum Gene Ther. 2010 Mar;21(3):271-83. doi: 10.1089/hum.2009.100.

Supplemental Content

Support Center